Scribe Therapeutics (SCTX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$33.3M

Revenue (quarter)

$1.9M

Revenue growth (year over year)

−60.84%

Gross profit (trailing twelve months)

$33.3M

Gross margin

100.00%

Net income (trailing twelve months)

−$32.3M

Net income (quarter)

−$6.5M

Net income growth (year over year)

+34.60%

Net margin

−97.00%

Return on equity

—

EPS (trailing twelve months)

−$13.13

Book value per share

—

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

176.80%

Payout ratio

—

Dividend yield

—

Company profile

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

• Is Scribe Therapeutics (SCTX) profitable?

  No. Scribe Therapeutics reported a net loss of $32.3M over the trailing twelve months.

• How much revenue does Scribe Therapeutics (SCTX) make?

  Scribe Therapeutics generated $33.3M in revenue over the trailing twelve months, down 60.84% year over year.

• How do I buy stock in Scribe Therapeutics (SCTX)?

  SCTX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.